erbB-2
(Synonyms: H2N-Lys-Ile-Phe-Gly-Ser-Leu-Ala-Phe-Leu-OH ) 目录号 : GP10132Tyrosine kinase (TK) receptor
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
erbB-2 is a transmembrane, tyrosine kinase (TK) receptor whose overexpression is associated with adverse prognosis in breast cancer1.
The human epidermal growth factor receptor (erbB-2) is a transmembrane receptor that is overexpressed in 15%–25% of breast cancers. erbB-2 overactivity is associated with adverse biological characteristics and poor clinical outcomes1.Overexpression of erbB2 in cell lines leads to transformation in the absence of a ligand2. None of the EGF family of ligands binds to ErbB2 directly. Therefore, in a technical sense, ErbB2 remains an orphan receptor.
A wide variety of human tumors contain an amplified or overexpressed erbB-2 gene, which encodes a growth factor receptor-like protein. When erbB-2 complementary DNA was expressed in NIH/3T3 cells under the control of the SV40 promoter, the gene lacked transforming activity despite expression of detectable levels of the erbB-2 protein. A further five- to tenfold increase in its expression under influence of the long terminal repeat of Moloney murine leukemia virus was associated with activation of erbB-2 as a potent oncogene. The high levels of the erbB-2 product associated with malignant transformation of NIH/3T3 cells were observed in human mammary tumor cells that overexpressed this gene3.
References:
1. V. Roy, E. A. Perez. Beyond Trastuzumab: Small Molecule Tyrosine Kinase Inhibitors in HER-2–Positive Breast Cancer The Oncologist 2009;14:1061–1069
2. Di Fiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR, Schlessinger J, Aaronson SA: Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 1987, 51:1063-1070.
3. P.P. Di Fiore, J. H. Pierce, M. H. Kraus, O. Segatto, C. R. King, S. A. Aaronson. erbB-2 is a Potent Oncogene When Overexpressed in NIH/3T3 Cells. Science, New Series, 237: 178-182
Cas No. | SDF | ||
别名 | H2N-Lys-Ile-Phe-Gly-Ser-Leu-Ala-Phe-Leu-OH | ||
Canonical SMILES | O=C(N[C@@H]([C@H](CC)C)C(N[C@@H](CC1=CC=CC=C1)C(NCC(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@H](C)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCCN)N | ||
分子式 | C50H78N10O11 | 分子量 | 995.21 |
溶解度 | ≥ 99.5mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.0048 mL | 5.0241 mL | 10.0481 mL |
5 mM | 0.201 mL | 1.0048 mL | 2.0096 mL |
10 mM | 0.1005 mL | 0.5024 mL | 1.0048 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。